» Articles » PMID: 34765363

Clinical Presentation of a COVID-19 Delta Variant Patient: Case Report and Literature Review

Overview
Journal Cureus
Date 2021 Nov 12
PMID 34765363
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe bilateral pneumonia and acute respiratory distress syndrome (ARDS) which can lead to difficulty breathing. Many cases require mechanical ventilation and intensive care unit management. The need for mechanical ventilation and ICU admission seems to be more evident in patients that were unvaccinated for COVID-19 at the time of admission. We discuss a case of a 63-year-old African-American woman who presented as a transfer to our hospital facility with acute hypoxic respiratory failure. She was already intubated and mechanically ventilated prior to her transfer. She had a one-week history of shortness of breath and cough productive of white, blood-tinged sputum. A two-day history of diarrhea was also reported before admission to the other hospital where she stayed for a week before transfer to our intensive care unit. She had no significant past medical history and was unvaccinated for COVID-19, and was suspected to be infected with the Delta strain of COVID-19. Her primary diagnosis at admission was COVID pneumonia and acute hypoxic respiratory failure. Her condition worsened over a period of one week. Chest X-Ray, at the time of arrival, showed bilateral patchy opacities consistent with COVID-19 pneumonia. After an extensive review of her labs and reports, the patient was attributed to be at a high risk for acute decompensation (or catastrophically ill), thus requiring critical care management. Over a course of 12 days, she was aggressively treated with antibiotics, steroids, remdesivir and tocilizumab. Her condition gradually deteriorated and she eventually passed away. It can be noted that most of the severe cases, especially ICU admissions, comprise people who are unvaccinated. We can safely conclude that although vaccination may not prevent re-infection, it does result in better clinical outcomes.

Citing Articles

Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody.

Saavedra D, Ane-Kouri A, Gregorich E, Mena J, Lorenzo-Luaces P, Londres H Immunol Lett. 2022; 251-252:1-8.

PMID: 36174772 PMC: 9512531. DOI: 10.1016/j.imlet.2022.09.005.


Development of lab score system for predicting COVID-19 patient severity: A retrospective analysis.

Sarkar A, Sanyal S, Majumdar A, Tewari D, Bhattacharjee U, Pal J PLoS One. 2022; 17(9):e0273006.

PMID: 36084080 PMC: 9462772. DOI: 10.1371/journal.pone.0273006.


Recapping the Features of SARS-CoV-2 and Its Main Variants: Status and Future Paths.

Ortega M, Garcia-Montero C, Fraile-Martinez O, Colet P, Baizhaxynova A, Mukhtarova K J Pers Med. 2022; 12(6).

PMID: 35743779 PMC: 9225183. DOI: 10.3390/jpm12060995.


COVID-19-related thrombotic complications experience before and during delta wave.

Manzur-Pineda K, ONeil C, Bornak A, Lalama M, Shao T, Kang N J Vasc Surg. 2022; 76(5):1374-1382.e1.

PMID: 35700857 PMC: 9188439. DOI: 10.1016/j.jvs.2022.04.053.

References
1.
Harvey W, Carabelli A, Jackson B, Gupta R, Thomson E, Harrison E . SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021; 19(7):409-424. PMC: 8167834. DOI: 10.1038/s41579-021-00573-0. View

2.
Fisman D, Tuite A . Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ. 2021; 193(42):E1619-E1625. PMC: 8562985. DOI: 10.1503/cmaj.211248. View

3.
Elliott P, Haw D, Wang H, Eales O, Walters C, Ainslie K . Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science. 2021; 374(6574):eabl9551. PMC: 10763627. DOI: 10.1126/science.abl9551. View

4.
Aziz M, Haghbin H, Sitta E, Nawras Y, Fatima R, Sharma S . Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. J Med Virol. 2020; 93(3):1620-1630. DOI: 10.1002/jmv.26509. View

5.
Mori H, Ohkawara H, Togawa R, Rikimaru M, Shibata Y, Ikezoe T . Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review. Int J Hematol. 2021; 113(3):320-329. PMC: 7868079. DOI: 10.1007/s12185-021-03084-z. View